## Index

Note: Page numbers in *italics* refer to figures; those in **bold** to tables.

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>acupuncture, CAM therapies</td>
<td>93</td>
</tr>
<tr>
<td>acute disseminated encephalomyelitis (ADEM)</td>
<td></td>
</tr>
<tr>
<td>acute treatment</td>
<td>150</td>
</tr>
<tr>
<td>autoimmune encephalitis</td>
<td>150</td>
</tr>
<tr>
<td>in children and adults</td>
<td>26</td>
</tr>
<tr>
<td>clinical presentation</td>
<td>149, 149, 149</td>
</tr>
<tr>
<td>cortical deficits/lesions</td>
<td>27</td>
</tr>
<tr>
<td>demyelinating attack</td>
<td>21</td>
</tr>
<tr>
<td>diagnosis</td>
<td>149–150</td>
</tr>
<tr>
<td>epidemiology</td>
<td>148</td>
</tr>
<tr>
<td>FLAIR MRI sequence, pediatric patient, 149</td>
<td></td>
</tr>
<tr>
<td>outcomes and long-term management</td>
<td>150</td>
</tr>
<tr>
<td>pathobiology</td>
<td>148</td>
</tr>
<tr>
<td>pediatric multiple sclerosis</td>
<td>77</td>
</tr>
<tr>
<td>ADEM see acute disseminated encephalomyelitis (ADEM)</td>
<td></td>
</tr>
<tr>
<td>ADF see ankle dorsiflexion (ADF)</td>
<td></td>
</tr>
<tr>
<td>adrenoleukodystrophy (ALD)</td>
<td>12</td>
</tr>
<tr>
<td>AFO see ankle foot orthosis (AFO)</td>
<td></td>
</tr>
<tr>
<td>ambulation</td>
<td></td>
</tr>
<tr>
<td>improvement</td>
<td>125</td>
</tr>
<tr>
<td>principles and perturbations</td>
<td>123</td>
</tr>
<tr>
<td>ankle dorsiflexion (ADF)</td>
<td>123</td>
</tr>
<tr>
<td>ankle foot orthosis (AFO)</td>
<td>125, 125–6</td>
</tr>
<tr>
<td>annualized relapse rate (ARR)</td>
<td>72, 73</td>
</tr>
<tr>
<td>antigen spreading</td>
<td></td>
</tr>
<tr>
<td>autoimmunity</td>
<td>12</td>
</tr>
<tr>
<td>CNS components</td>
<td>11</td>
</tr>
<tr>
<td>myelin antigens</td>
<td>11</td>
</tr>
<tr>
<td>Theiler’s murine encephalomyelitis</td>
<td>12</td>
</tr>
<tr>
<td>anti-JCV antibody titer</td>
<td>52</td>
</tr>
<tr>
<td>antioxidants</td>
<td>93–4, 96</td>
</tr>
<tr>
<td>AQP4 see Aquaporin-4 (AQP4)</td>
<td></td>
</tr>
<tr>
<td>aquaporin-4 (AQP4)</td>
<td>153–4, 160</td>
</tr>
<tr>
<td>ARR see annualized relapse rate (ARR)</td>
<td></td>
</tr>
<tr>
<td>aseptic meningitis</td>
<td>166–7, 167</td>
</tr>
<tr>
<td>atherosclerosis</td>
<td>8</td>
</tr>
</tbody>
</table>

*Bezch disease (BD)* see *neuro-Bezch syndrome (NBS)*

black holes
- evidence, 53
- MRI presentation, 34, 39, 51
- T1 sequence, 23

*Borrelia burgdorferi*, 169

bracing, physical rehabilitation, 125, 125

brain atrophy, 29, 34, 40, 62

breastfeeding, 74–5

Brief International Cognitive Assessment, 117, 118

BVT see *bee venom therapy (BVT)*

CAM therapies see *complementary and alternative medicine (CAM) therapies*

Center for Epidemiological Research Screen for Depression (CES-D), 119

cerebral neurosarcoidosis, 167

cerebral venous sinus thrombosis (CVST), 182–3, 190

see also extra-axial NBS

chronic obstructive pulmonary disease (COPD), 8

clinically isolated syndromes (CIS)
- cognitive impairment, 118
- cognitive rehabilitation, 131
- diagnostic process, MS, 21, 25
- pediatric multiple sclerosis, 78
- relapsing MS, 49, 52

cognitive impairment assessment
- Brief International Cognitive Assessment, 117, 118
- interview, 117
- neuropsychological tests, 117
- Symbol Digit Modalities Test, 117, 118
- caregiver burden, 117

pathogenesis
- clinically isolated syndrome (CIS), 118
- diffusion tensor imaging, 118
- neuroradiologic markers, 118
- radiologically isolated syndrome, 118
cognitive impairment (cont’d)
treatment
  interferon-beta-1a, 118
  nonpharmacological options, 119
  Paced Auditory Serial Addition Test (PASAT), 118
cognitive rehabilitation
  clinically isolated syndrome (CIS), 131
  in-office assessments, 131
  neuropsychological testing (NPT), 131
  nonpharmacological treatment, 132
  preliminary cognitive testing, 131
  speech language pathologist (SLP), 131
combination therapy, MS, 54
complementary and alternative medicine (CAM) therapies
  acupuncture, 93
  antioxidants, 93
  bee venom therapy, 94
  cooling therapy, 94–5
  cranberry, 95
  diets, 95–6
  Echinacea and immune-stimulating supplements, 96
  Ginkgo biloba, 96–7
  guided imagery, 97
  LDN, 97
  marijuana (cannabis), 97–8
  massage, 98
National Institutes of Health (NIH) classification, 91, 92
  reflexology, 98–9
  risk–benefit profiles, 92, 93
  Tai chi, 99
  TCM, 93
terminology, 91
  unconventional medicine uses, 91–3
  vitamin B12, 99
  yoga, 100
contrast enhancement, MRI, 34
cranial neuropathy, 167–8
CVST see cerebral venous sinus thrombosis (CVST)
cyclophosphamide
  pediatric multiple sclerosis, 85–6
  progressive MS treatment algorithms, 59, 60, 63, 64
  relapsing MS, 54
  sex-determined issues, 69, 70
Dawson’s fingers, 23, 34
deep brain stimulation (DBS), 129
depression assessment
  Beck Fast Screen for depression, 119
  Center for Epidemiological Research Screen for Depression (CES-D), 119
  DSM-IV-TR diagnostic criteria, 119
  follow-up interview, 119
  Hamilton Rating Scales, 119
  Hospital Anxiety and Depression Scale, 119
  sleep history, 120
  social support, 120
pathogenesis, 120
treatment
  antidepressant medication, 120
  mindfulness-based stress reduction programs, 121
  psychiatric referral, 120
diagnostic process, MS
  acute hemorrhagic leukoencephalitis, 26
  ADEM, 26–7
  ancillary testing, 25
defining MS
  demyelinating lesions, 18–19
  revised McDonald criteria, 18
sclerosis, 18
  silent attacks, 18
disease courses
  ADEM, 21
  bulbar dysfunction, 19
  clinically isolated syndrome (CIS), 21
  dissemination in time (DIT), 21
  MS relapse, 19
  pre-existing deficits, 19
  PRMS, 19, 20
  RRMS, 19–21, 20
  SPMS, 19, 20
encephalopathy, 27
examination findings, 25, 26
historical features, 25, 26
  MRI, 23, 24
multiple cranial neuropathies, 27
NMO, 26
revised McDonald criteria, 23–5, 24
symptoms
  ataxia, 22, 22–3
  Marcus Gunn pupil, 22
  neuropathic pain, 23
  posterior fossa symptoms, 22
  pseudoexacerbation, 21
  sensory disturbance, 22, 22
  Uhthoff’s phenomenon, 21–2
Index - 193

urinary urgency, 23
visual loss, 22, 22
weakness, 21, 22
diets, CAM therapies
  fish oil, generally regarded as safe (GRAS), 96
  omega-6 fatty acids, 96
  omega-3 supplements, 95–6
  polyunsaturated fatty acids (PUFAs), 95–6
  Swank diet, 95
  vitamin E dose, 96
diffusion-weighted imaging, 32, 41–2, 42
DIR see double inversion recovery (DIR)
Disability Status Scale (DSS), 57, 80
disease-modifying drugs (DMD), 45–7, 46–7
disease-modifying therapies (DMTs)
  clinical trials, 59, 59
  fertility and, 69
  pediatric multiple sclerosis
    anxiety, 82
    glatiramer acetate, 85
    interferon-beta, 83–5
    sexually active adolescents, 83
    treatment algorithm, 83, 84
  pregnancy and MS patient, 73, 74
  reproductive issues, in MS, 69, 70
disease response monitoring, 51
dissemination in space (DIS), 24, 27, 36
dissemination in time (DIT), 21, 24, 27, 36
DLP see dysesthetic limb pain (DLP)
DMD see disease-modifying drugs (DMD)
DMT see disease-modifying therapies (DMTs)
double inversion recovery (DIR), 34
dysesthetic limb pain (DLP), 108–9, 109

EAE see experimental allergic encephalomyelitis (EAE)
EBV see Epstein–Barr virus (EBV)
Echinacea and immune-stimulating supplements, 96
EDSS see Expanded Disability Status Scale (EDSS)
enzyme-linked immunosorbent assay (ELISA), 157, 173, 174
epitope spreading, 12
Epstein–Barr virus (EBV)
  adolescence and young adulthood, 7
  anti-EBNA-1 antibodies, 7
  anti-Epstein–Barr nuclear antigen (EBNA)
    complex, 7
  infectious mononucleosis (IM), 6–7
  seronegative adults, 7
  escalation, MS, 54
etiology, MS
  combining risk factors, 8
environment role
  Epstein–Barr virus (EBV), 6–7
  geography, 4
  infection, 6
  migration studies and timing, 4–5
  risk factors, 3–4
  smoking, 7–8
  vitamin D, 4, 5–6
gender effects, 3
genes
  autoimmune hypothesis, 3
  familial aggregation, 1
  growth and repair mechanisms, 3
  human leukocyte antigen (HLA), susceptibility, 2
  IL-7/IL-2 receptors, 3
  parent-of-origin, 2
  susceptibility, 2
Expanded Disability Status Scale (EDSS)
  axonal density and disability, 41, 58, 161
  and cognitive impairment, 117
  menstrual cycle and menopause, 69
  neuromyelitis optica, 160
  progressive MS treatment algorithms, 58–61, 59
  relapsing MS, 45, 49, 51–4
experimental allergic encephalomyelitis (EAE), 68, 93
extra-axial NBS
  Behçet disease, nervous system involvement, 182–3
  cerebral venous sinus thrombosis, 190
  differential diagnosis, 187–8
  and systemic major vessel disease, 183
fatigue
  assessment
    antispasticity medications, 115
    depressed mood, 115
    depression and sleepiness, 114
    Fatigue Severity Scale, 115
    features, 114
    Modified Fatigue Impact Scale, 115
  sleep disorders, 115
  subjective, 114
management
  exercise, 115–16
  non-pharmacological interventions, 117
  primary treatment, 115
  psychological and behavioral interventions, 116
  treatment algorithm, 116
pathogenesis, 115
Fatigue Severity Scale, 115
female cancers, 75
fingolimod, 11, 13, 48, 52, 53, 61–5

GBS See Guillain-Barré syndrome (GBS)
genome–wide association study (GWAS), 2–3, 6
Ginkgo biloba, herbal therapy, 96–7
glatiramer acetate (GA)
contraceptive issues, 69
neuromyelitis optica treatment, 159
pregnancy and, 73
progressive MS, clinical trial, 58–60, 62
gray matter pathology, 10
guided imagery, CAM therapies, 97
Guillain–Barré syndrome (GBS), 171

Hamilton Rating Scales, 119
hip girdle stability, 123–4, 124
Hospital Anxiety and Depression Scale, 119
human herpesvirus-4 (HHV-4) see Epstein–Barr virus (EBV)

IgG index, 25
IM see infectious mononucleosis (IM)
immune reconstitution inflammatory syndrome (IRIS), 54
immunopathogenesis, MS
antigen spreading, 11–12
as autoimmune disease, 11
autoimmunity, trigger(s), 16
B cells and humoral immunity, 14
candidates, self-antigen in MS, 11
cytokines role
antiinflammatory, 15
IFN-γ, 16
IL-2, 16
IL-10, 16
proinflammatory, 15–16
TGF-β, 16
TNF-α, 16
dendritic cells and astrocytes
CNS, immune surveillance, 15
cytokines production, 15
differentiation and maturation, 15
gliosis, 15
T cell activation and expansion, 15
epitope spreading, 12
gray matter pathology, 10
immunemediated disease, 11
lymphocyte trafficking, CNS, 13

microglia and macrophages, 14–15
myelin proteins, 14
neuropathology, 10
outside-in vs. inside-out
adrenoleukodystrophy (ALD), 12
gadolinium enhancement, 13
MR spectroscopy and magnetization transfer, 13
T cells role, 13–14
infectious mononucleosis (IM), 6–7
interferon (IFN)-beta, 58, 59–60
International Multiple Sclerosis Genetics Consortium (IMSGC), 2, 3
International Pediatric Multiple Sclerosis Study Group (IPMSSG), 77, 78, 85
intra-axial NBS, 183, 186–190
IRIS see immune reconstitution inflammatory syndrome (IRIS)

knee control, physical rehabilitation, 123
Kurtzke EDSS, 51

LDN see low-dose naltrexone (LDN)
LETM see longitudinally extensive transverse myelitis (LETM)
longitudinally extensive transverse myelitis (LETM), 153, 156, 158
low-dose naltrexone (LDN), 97
lyme neuroborreliosis
B. burgdorferi infection, 169
cranial neuropathies, 171
diagnosis
antibody response, 173, 174
Borrelia infection, 173
clinical criteria, 172
CNS neuroborreliosis, 173
CSF analysis, 173
ELISA, 173
encephalomyelitis, 173, 175
PET/SPECT, 175
urine antigen test, 173
distribution, pareses, 170, 170
GBS, 171
Ixodes tick, 169
lymphocytic meningitis, 171, 175
neurosarcoidosis, 175
nonneurologic manifestations, 169–170
optic neuritis, 171
post-Lyme syndrome, 172
radiculoneuritis, 171
sleep disturbances, 175
subacute encephalopathy/encephalitis, 171
transverse myelitis, 172
methylprednisolone (MP), 61
methotrexate, 60
mitoxantrone, 58, 60
Modified Fatigue Impact Scale, 115
MTR see magnetization transfer ratio (MTR)
MS see multiple sclerosis (MS)
MTR see magnetization transfer ratio (MTR)
multiphasic ADEM, 78
multiple cranial neuropathies, 27
multiple sclerosis (MS) CAM therapies, 91–100
diagnostic process, 18–27
etiology see etiology, MS
immunopathogenesis, 10–16
invisible symptoms, 114–121
monitoring see magnetic resonance imaging (MRI), MS
pediatric multiple sclerosis see pediatric multiple sclerosis
progressive MS treatment algorithms, 57–65
psychosocial adaptation, 134–143
rehabilitation see rehabilitation
relapsing see relapsing, MS
symptomatic management see symptomatic management
myelopathy, 166–7
myopathy, 168
natalizumab pediatric multiple sclerosis, 85
progressive MS treatment algorithms, 59, 63
relapsing MS, 45, 48, 49, 52, 63
rescue therapy, 54
NAWM see normal-appearing white matter (NAWM)
neuro-Behçet syndrome (NBS)
CVST, 190
description, 178
diagnostic studies
CSF, 185–6
extra-axial, 187–8
intra-axial, 186–7, 188
neuroimaging, 185, 186, 187
epidemiology, 178
nervous system arterial disease, 183
cognitive changes, 183–4
extra-axial, 182–3
headache, 184–5
intra-axial, 183, 184
neurobehavioral syndrome, 183
neuroimaging studies, 181
magnetic resonance imaging (MRI), MS
ADEM, 149
atrophy, 33
black holes, 34, 39, 51
brain atrophy, 34
consensus protocol for clinical evaluation, 36, 37
gadolinium chelates, dose, 36
spinal cord imaging, 36, 38
T₂-FLAIR images, 37, 39
contrast enhancement, 34
conventional, 32, 40
2010 criteria, 29, 30–31
diagnostic criteria, 36
disease monitoring and treatment
brain atrophy, 40
conventional, 40
follow-up MRI scanning, 39–40
lesion activity, 40
lesion location, 33–4
lesions, 32, 33
limitations, conventional MRI, 40
nonconventional
diffusion-weighted imaging, 32, 41–2, 42
magnetization transfer imaging, 32, 41
perfusion-weighted imaging, 32, 42, 42
susceptibility-weighted imaging, 32, 41, 42
pediatric MS
in ADEM, 81
lesion dissemination, McDonald criteria, 80
MS diagnosis in children, 80, 80
in pediatric MS, 81
T₂ hyperintense lesions, 80
T₁-weighted hypointense lesions (black holes), 80
pregnancy, 73–4
progressive MS treatment algorithms, 57–8
relapsing, MS, 52
signal intensity and morphology, 32–3
spinal cord, 35, 35–6
magnetization transfer ratio (MTR), 41
male sex hormones, 75
marijuana (cannabis)
cannabinoids (CBs), 97–8
side effects, 98
tetrahydrocannabinol (THC), 97–8
massage, CAM therapies, 98
neuro-Behçet syndrome (NBS) (Cont’d)
neurological spectrum, 181, 182
parenchymal-CNS involvement and CVST, 181
PNS involvement, 181, 185
subclinical study, 185
pathology and etiopathogenesis
autoinflammatory diseases, 180
fibrinolytic defects, 180–181
immunological and genetic factors, 180–181
innate and adaptive immune systems, 180
vasculitis, 180
systemic manifestations and diagnosis
amyloidosis, 180
cardiovascular involvement, 180
criteria and definition, 178, 179
gastrointestinal involvement, 180
genital ulceration, 179
laboratory investigations, 180
musculoskeletal involvement, 179–180
oral aphthae, 178–9
pathery phenomenon, 179
skin lesions, 179
treatment
acute episodes, 188, 189
long-term treatments, 188, 190
neuromyelitis optica (NMO)
autoantibody, 153
description, 153
diagnosis
acute attacks, 154
autoimmunity, 155
chronic pain, 155
clinical and nonclinical criterion, 155
demographic features, 153–4
long-term course/disability, 154–5
opticospinal MS, 155–6
relapsing vs. monophasic, 156
spectrum disorder, 155
investigations
CSF, 157
gadolinium administration, 158
MRI, 157, 157, 158
optical coherence tomography (OCT), 158
serology, 157
visual evoked potentials (VEP), 158
MS-typical brain MRI lesions, 158
optimal attack-prevention treatment, 158
prognosis and follow-up
antibody serology and titers, 161
disability measurement, 160–161
sarcoidosis, 158–9
transverse myelitis, 159
treatment
acute treatment, 159
AQP4, 160
autoimmunity, 160
in vitro and in vivo studies, 160
long-term treatment, 159–160
open-label study, 160
plasma exchange (PLEX), 160
stem cell transplantation, 160
neurosarcoidosis (NS)
aseptic meningitis, 166, 167
cranial neuropathy, 167–8
diagnosis
algorithm, 164
biopsy, 164
clinical localization, 164, 164
definition, 163
FLAIR MRI, 165, 165
and staging, 164
dosages, 166
 genetic predisposition, 163
ischemic strokes, 167
multifocal intracranial lesions, 167
myelopathy, 166–7
parenchymal cerebral hemorrhages, 167
peripheral neuropathy and myopathy, 168
prognosis and long-term monitoring, 168
treatment
corticosteroids and immunosuppressant agents, 165
low-dose radiation therapy reports, 166, 166
randomized controlled comparative studies, 165
strategies, 166
Neutralizing antibodies (NAbs) testing, 49, 52
NMO-IgG seropositive, 156–7
normal-appearing white matter (NAWM), 41
NS see neurosarcoidosis (NS)
OCBs see oligoclonal bands (OCBs)
OCT see optical coherence tomography (OCT)
oligoclonal bands (OCBs), 14, 25
optical coherence tomography (OCT), 25, 158
opticospinal MS, 155–6
organ rehabilitation
anti-muscarinic agents, 131
antimuscarinics and catheterization, 130
bladder dysfunction, 130–131
detrusor-sphincter dyssynergia (DSD), 130
urodynamic testing, 130
Paced Auditory Serial Addition Test (PASAT), 118
pain
categories, 107
CNS origin, treatment, 107
constant pain, 108–9, 109
diabetic neuropathy, 106
ectopic impulses, 106
mechanism, 106
TN see trigeminal neuralgia (TN)
paroxysmal pain see pain
pediatric multiple sclerosis
acute demyelinating attacks treatment, 82
acute disseminated encephalomyelitis (ADEM), 77
awareness, 89
clinically isolated syndromes (CIS), 78
clinical outcome, 78
clinical presentation, 79
cognitive dysfunction and quality of life
considerations
academics, 86
depression and anxiety, 89
intelligence quotient (IQ), 86
neuropsychological testing, 86
practitioners and physician, 89
definition, 78
diagnostic considerations
evoked potentials, 81
MRI, 80–81
spinal fluid, 81
differential diagnosis, 82, 83
disease course
demyelinating event and subsequent relapse interval, 79
Disability Status Scale (DSS) scores, 80
mean annualized relapse rate, 79
secondary progression, 80
disease-modifying therapies (DMTs), 82–5
epidemiology and risk factors
environmental risk factors, 79
female/male ratio, 78–9
hormonal influences, 78–9
prevalence data, 78
remote infection, 79
vitamin D concentrations, 79
escalation of care
cyclophosphamide, 85–6
natalizumab, 85
rituximab, 86
treatment, inadequate response, 85
International Pediatric Multiple Sclerosis Study Group (IPMSSG), 77
intravenous immunoglobulin (IVIG), 82
multiphasic ADEM, 78
recurrent ADEM, 78
symptomatic therapy, 86, 87–8
perfusion-weighted imaging, 32, 42, 42
peripheral nervous system (PNS), 181, 185
peripheral neuropathy (PN), 168
physical rehabilitation
ambulation see ambulation
ankle dorsiflexion (ADF), 123
assistive devices
for ambulation, 126–7, 127
handheld ADs, 126, 127
power chair, 127–8
wheelchairs, 127
bracing, 125–6
dalfampridine, 123
exercise-based programs, 128–9
functional electrical stimulation (FES), 126
hip girdle stability, 123–4, 124
home modifications, 129–130
knee control, 123
pharmacologic approach, 129
spasticity see spasticity
upper extremity function, 129
PN see peripheral neuropathy (PN)
PNS see peripheral nervous system (PNS)
PPMS see primary progressive MS (PPMS)
nRTMUS trial, 74
POPART’MUS trial, 74
Pregnancy and Multiple Sclerosis (PRIMS) trial, 71–2
primary progressive MS (PPMS)
  ancillary testing, 25
  IFN-beta-1a, intramuscular (IM) form, 59
  MRI, 21
  MS disease courses, 19, 20
  progressive MS treatment algorithms, 57
PRMS see progressive relapsing MS (PRMS)
progressive MS treatment algorithms
  bone health, 65
clinical trials
  challenges, 58
  cyclophosphamide, 60
  disease-modifying therapy, 59
  EDSS, 61
  glatiramer acetate, 60
  interferon (IFN)-beta, 58, 59–60
  methotrexate, 60
  methylprednisolone, 61
  mitoxantrone, 58, 60
  natalizumab and fingolimod, 61
  randomized placebo-controlled clinical trial, 61
  rituximab, 61
cortical lesions, 58
Disability Status Scale (DSS), 57
IVMP, routine uses, 63, 65
JC virus antibody testing, 64
MRI studies, 57–8
natalizumab/fingolimod, 63–4
neuroprotective strategies, 64–5
patient reluctance, 64
PPMS, 57, 63
progressive multifocal leukoencephalopathy, 64
routine immunizations, 65
SPMS, 57, 63
stopping disease-modifying therapy, 64
treatment, 63
Wallerian degeneration, 58
progressive relapsing MS (PRMS), 19, 20
psychosocial adaptation
  accommodation phase, 142–3
  chronic phase
    couples issues, 141
    identity, 140
    personality issues and personal history, 141–2
    risks, 142
    social isolation and social support, 140–141
coping and, 134
CSF findings, 166, 167
description, 134
interim/transitional phase, 139–140
prediagnosis phases
  crisis phase, 136
defenses, 139
disclosure, 139
education, 136
healthcare professionals, 138
neurologists, 138
patients hope, 137–8
presymptomatic, 135
sadness and anger, 137
social support, 139
suicide, 137
symptomatic, 135–6
stages and phases
  chronic illness, 135
  interventions, 135
  time phases, 134, 135
radiologically isolated syndrome (RIS), 24–5
randomized placebo-controlled clinical trial, 61
recurrent ADEM, 78
reflexology, CAM therapies, 98–9
rehabilitation
  cognitive, 131–2
  organ, 130–131
  physical see physical rehabilitation
relapsing, MS
  advancement, 54
cerebrospinal fluid (CSF) analysis, 48–9
combination therapy, 54
DMD, 45–7, 46–7
EDSS progression, 45
escalation, 54
immunomodulation, 45
initiation
  aggressive course, 53
  black holes, evidence, 53
  first-line agent, 52
  induction strategy, 53
  second-line agent, 53
mitoxantrone, 45, 48, 52–4
natalizumab, 45, 48, 49, 52–4
neutralizing antibodies (NAbs), 49
pathology versus clinical course, 48
prognostic factors, 48–9
rescue therapy, 54
secondary progressive (SP) MS, 45
suboptimal response
  intolerance, lateral therapy, 53
treatment failure, 53–4
therapy
  anti-JCV antibody titer, 52
Index • 199

decision-making, factors affecting, 49
disease response monitoring, 51
drug side effects, detection, 51
guidelines, 51
Kurtzke EDSS, 51
MRI, 52
NAb testing, 52
patient adherence, 49–51
pre- and postmedication laboratory tests, 50, 51
relapse parameters, 51
Rio scoring system, 51–2
relapsing–remitting MS (RRMS), 18–21, 20, 67
reproductive issues, in MS
congenital effects, 70–71
contraceptive issues, 69–70
disease-modifying therapies (DMTs), 69, 70
fertility, 69
menstrual cycle and menopause, 69
oral contraceptive pills (OCPs), 69–70
pregnancy safety categories, 69, 70
Rio scoring system, 51–2
RIS see radiologically isolated syndrome (RIS)
rituximab, 54, 61, 86, 159
RRMS see relapsing–remitting MS (RRMS)
secondary progressive MS (SPMS), 19, 67 see also
   progressive MS treatment algorithms
sex-determined issues
breastfeeding, 74–5
epidemiology and gender
   immune cells, composition, 67
   lupus and rheumatoid arthritis, 67
   relapsing–remitting MS (RRMS), 67
   secondary progressive MS (SPMS), 67
   vitamin D levels, 67
female cancers, 75
male sex hormones, 75
pregnancy and MS patient see pregnancy and MS patient
reproductive issues see reproductive issues, in MS
sex hormone and chromosome differences
   actions, 68
   experimental autoimmune encephalomyelitis (EAE), 68
   gender effects, 68–9
   neuroprotective agents, 68
   Th2 immune shifts, 68
short-tau inversion recovery (STIR) images, 35
sleep history, depression, 120
smoking, 7–8
spasticity
assessment, 125
baclofen, 110–111
benzodiazepines, 111
BTX, presynaptic acetylcholine blocking, 111
cannabinoids, 111
gabapentin, 111
intrathecal (IT) baclofen pump, 111
knee buckling, 124, 125
pharmacologic management, 112
plantar flexion spasticity, 124
quadriceps, 125
reduction
   chemodenervation, 128
   phenol neurolysis, 128
tizanidine, 111
spinal cord, MRI, 35, 35–6
spinal fluid
   neuromyelitis optica, 157
   neurosarcoïdosis, 167
   pediatric multiple sclerosis, 81
SPMS see secondary progressive MS (SPMS)
susceptibility-weighted imaging, 32, 41, 42
Symbol Digit Modalities Test, 117, 118
symptomatic management
   bladder dysfunction
      anticholinergic agents, 103
      botulinum toxin (BTX)-A injections, 103
detrusorsphincter dyssynergia (DSD), 102
   intermittent straight catheterization (ISC), 103
   intranasal desmopressin (DDAVP), 103
   management algorithm, 104
   neurogenic bladder, 102
   nonselective antimuscarinics, 103
   postvoid residual urine volume (PVR), 103
   suprapontine cerebral lesions, 102
   suprasacral spinal cord lesions, 102
   urinary tract infection(UTI), 102–3
   bowel dysfunction
      constipation, 104
      fecal incontinence, 104–5
   impaired gait, 110, 110
   pain see pain
   sexual dysfunction (SD)
      anticholinergic agents, 103, 105
      external vibratory stimulation, 106
      men, symptoms, 105
      neurogenic ED, 105
      PDE-5 inhibitors, for ED, 105
   secondary SD, treatment, 106
   self-administered screening, 106
symptomatic management (Cont’d)
  vaginal lubricants, 106
  women, 105
  spasticity, 110–111
  tremor, 111–12, **112**

Tai chi, CAM therapies, 99
TCM see Traditional Chinese medicine (TCM)
TM see transverse myelitis (TM)
TN see trigeminal neuralgia (TN)

Traditional Chinese medicine (TCM), 93
transverse myelitis (TM)
  acute treatment, 147–8
  clinical presentation, 145
  diagnosis, 145–7, **146**, 146
  epidemiology, 144–5
  outcomes and long-term management, 148
  pathobiology, 145
  patients, standard evaluation, **147**

trigeminal neuralgia (TN)
  carbamazepine, 107
  conventional surgical approaches, 107
  glossopharyngeal and occipital neuralgia, 108
  Lhermitte's phenomenon, 108
  management algorithm, **108**
  optic neuritis, 108
  treatments, **107**

urinary tract infections (UTIs) treatment, 95

VEP see visual evoked potentials (VEP)
visual evoked potentials (VEP), 158

vitamin D
  CAM therapies, 99–100
  etiology, MS, 4, 5–6
  levels, 67
  MS, risk factors, 5
  pediatric multiple sclerosis, 79
  pleiotropic actions, 5
  relative risk (RR), 5
  serum concentrations, 4
  skin exposure to sunlight, 5
  vitamin D response element (VDRE), 6

Wallerian degeneration, 58

yoga, CAM therapies, 100